Supplemental data file 1. References used in ChromSorter PC
[1-15][16-41][42-74][75-107][108-149][150-192][193-223][224-250]
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Atkin NB, Baker MC: Chromosome 7q deletions: observations on 13
malignant tumors. Cancer Genet Cytogenet 1993, 67(2):123-125.
Atkin NB, Baker MC: Chromosome study of five cancers of the prostate. Hum
Genet 1985, 70(4):359-364.
Atkin NB, Baker MC: Chromosome 10 deletion in carcinoma of the prostate.
N Engl J Med 1985, 312(5):315.
Astrom L, Weimarck A, Aldenborg F, Delle U, Hanson C, Verbiene I, Danielsson
A, Hammarsten J, Kopf I: S-phase fraction related to prognosis in localised
prostate cancer. No specific significance of chromosome 7 gain or deletion of
7q31.1. Int J Cancer 1998, 79(6):553-559.
Arps S, Rodewald A, Schmalenberger B, Carl P, Bressel M, Kastendieck H:
Cytogenetic survey of 32 cancers of the prostate. Cancer Genet Cytogenet
1993, 66(2):93-99.
Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ,
Schroder FH, van Dekken H: Identification of genetic markers for prostatic
cancer progression. Lab Invest 2000, 80(6):931-942.
Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, van Dekken
H: Interphase cytogenetics of prostatic adenocarcinoma and precursor
lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic
intraepithelial neoplasias. Genes Chromosomes Cancer 1995, 12(4):241-250.
Alers JC, Krijtenburg PJ, Vissers CJ, Bosman FT, van der Kwast TH, van Dekken
H: Cytogenetic heterogeneity and histologic tumor growth patterns in
prostatic cancer. Cytometry 1995, 21(1):84-94.
Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC,
van Der Kwast TT, Schroder FH, Tanke HJ, van Dekken H: Molecular
cytogenetic analysis of prostatic adenocarcinomas from screening studies :
early cancers may contain aggressive genetic features. Am J Pathol 2001,
158(2):399-406.
Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van
der Kwast TH, Bosman FT, van Dekken H: Interphase cytogenetics of prostatic
tumor progression: specific chromosomal abnormalities are involved in
metastasis to the bone. Lab Invest 1997, 77(5):437-448.
Alers JC, Krijtenburg PJ, Hop WC, Bolle WA, Schroder FH, van der Kwast TH,
Bosman FT, van Dekken H: Longitudinal evaluation of cytogenetic
aberrations in prostatic cancer: tumours that recur in time display an
intermediate genetic status between non-persistent and metastatic tumours. J
Pathol 1998, 185(3):273-283.
Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ,
Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected
by fluorescence in situ hybridization are markers of poor prognosis in
prostate cancer. Cancer Res 1994, 54(15):3998-4002.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Alcaraz A, Barranco MA, Corral JM, Ribal MJ, Carrio A, Mallofre C, Llopis J,
Cetina A, Alvarez-Vijande R: High-grade prostate intraepithelial neoplasia
shares cytogenetic alterations with invasive prostate cancer. Prostate 2001,
47(1):29-35.
Ahman AK, Jonsson BA, Damber JE, Bergh A, Emanuelsson M, Gronberg H:
Low frequency of allelic imbalance at the prostate cancer susceptibility loci
HPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes
Chromosomes Cancer 2000, 29(4):292-296.
Afonso A, Emmert-Buck MR, Duray PH, Bostwick DG, Linehan WM, Vocke
CD: Loss of heterozygosity on chromosome 13 is associated with advanced
stage prostate cancer. J Urol 1999, 162(3 Pt 1):922-926.
Babu VR, Miles BJ, Cerny JC, Weiss L, Van Dyke DL: Cytogenetic study of
four cancers of the prostate. Cancer Genet Cytogenet 1990, 48(1):83-87.
Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar D,
Hopper JL, Bishop DT, Moller P et al: Suggestive evidence for a site specific
prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial
Prostate Cancer Study Coordinators and Collaborators. The EU Biomed
Collaborators. J Med Genet 2000, 37(12):947-949.
Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC,
Chung LW, Liang JC: Trisomy 7: a potential cytogenetic marker of human
prostate cancer progression. Genes Chromosomes Cancer 1994, 9(1):19-27.
Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Lohrs U:
Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic
in situ hybridization. Cancer Res 1994, 54(16):4472-4480.
Barranco MA, Alcaraz A, Corral JM, Sole M, Mallofre C, Llopis J, Rodriguez A,
Ribal MJ, Alvarez-Vijande R, Carretero P: Numeric alterations in
chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate
with high-grade localized prostate cancer. Eur Urol 1998, 34(5):419-425.
Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA: Evidence
of chromosomal instability in prostate cancer determined by spectral
karyotyping (SKY) and interphase fish analysis. Neoplasia 2001, 3(1):62-69.
Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of
chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes
Chromosomes Cancer 1991, 3(3):215-220.
Bergthorsson JT, Johannesdottir G, Arason A, Benediktsdottir KR, Agnarsson
BA, Bailey-Wilson JE, Gillanders E, Smith J, Trent J, Barkardottir RB: Analysis
of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum
Genet 2000, 107(4):372-375.
Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy B, Dutrillaux B:
Characterization of chromosome changes in two human prostatic carcinoma
cell lines (PC-3 and DU145) using chromosome painting and comparative
genomic hybridization. Cancer Genet Cytogenet 1997, 96(2):123-128.
Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK, Peterson
BJ, Wang ZY, Carpten JD, Roberts SG et al: Linkage analyses at the
chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
families with hereditary prostate cancer. Am J Hum Genet 2000, 66(2):539546.
Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM,
Thibodeau SN, Schaid DJ: Evidence for a prostate cancer-susceptibility locus
on chromosome 20. Am J Hum Genet 2000, 67(1):82-91.
Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A,
Millasseau P, Mellah I, Cohen N et al: Predisposing gene for early-onset
prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998,
62(6):1416-1424.
Berube NG, Speevak MD, Chevrette M: Suppression of tumorigenicity of
human prostate cancer cells by introduction of human chromosome
del(12)(q13). Cancer Res 1994, 54(12):3077-3081.
Bishop DT, Kiemeney LA: Family studies and the evidence for genetic
susceptibility to prostate cancer. Semin Cancer Biol 1997, 8(1):45-51.
Bock CH, Cunningham JM, McDonnell SK, Schaid DJ, Peterson BJ, Pavlic RJ,
Schroeder JJ, Klein J, French AJ, Marks A et al: Analysis of the prostate
cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer.
Am J Hum Genet 2001, 68(3):795-801.
Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs
SC, Robinson JC, Epstein JI, Walsh PC et al: Homozygous deletion and
frequent allelic loss of chromosome 8p22 loci in human prostate cancer.
Cancer Res 1993, 53(17):3869-3873.
Bova GS, Isaacs WB: Review of allelic loss and gain in prostate cancer. World
J Urol 1996, 14(5):338-346.
Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB: Physical
mapping of chromosome 8p22 markers and their homozygous deletion in a
metastatic prostate cancer. Genomics 1996, 35(1):46-54.
Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R: Metaphase
cytogenetics and DNA flow cytometry with analysis of S-phase fraction in
prostate cancer: influence on prognosis. Urology 1996, 47(2):218-224.
Breitkreuz T, Romanakis K, Lutz S, Seitz G, Bonkhoff H, Unteregger G, Zwergel
T, Zang KD, Wullich B: Genotypic characterization of prostatic carcinomas: a
combined cytogenetic, flow cytometry, and in situ DNA hybridization study.
Cancer Res 1993, 53(17):4035-4040.
Brothman AR: Cytogenetic studies in prostate cancer: are we making
progress? Cancer Genet Cytogenet 1997, 95(1):116-121.
Brothman AR, Patel AM: Characterization of 10 marker chromosomes in a
prostatic cancer cell line by in situ hybridization. Cytogenet Cell Genet 1992,
60(1):8-11.
Brothman AR, Peehl DM, Patel AM, MacDonald GR, McNeal JE, Ladaga LE,
Schellhammer PF: Cytogenetic evaluation of 20 cultured primary prostatic
tumors. Cancer Genet Cytogenet 1991, 55(1):79-84.
Brothman AR, Steele MR, Williams BJ, Jones E, Odelberg S, Albertsen HM,
Jorde LB, Rohr LR, Stephenson RA: Loss of chromosome 17 loci in prostate
cancer detected by polymerase chain reaction quantitation of allelic markers.
Genes Chromosomes Cancer 1995, 13(4):278-284.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
Brothman AR, Watson MJ, Zhu XL, Williams BJ, Rohr LR: Evaluation of 20
archival prostate tumor specimens by fluorescence in situ hybridization
(FISH). Cancer Genet Cytogenet 1994, 75(1):40-44.
Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB:
Chromosomal aneusomies detected by fluorescent in situ hybridization
analysis in clinically localized prostate carcinoma. J Urol 1994, 152(4):11571162.
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC:
Functional identification of LZTS1 as a candidate prostate tumor suppressor
gene on human chromosome 8p22. Oncogene 2001, 20(31):4169-4179.
Cancel-Tassin G, Latil A, Valeri A, Guillaume E, Mangin P, Fournier G, Berthon
P, Cussenot O: No evidence of linkage to HPC20 on chromosome 20q13 in
hereditary prostate cancer. Int J Cancer 2001, 93(3):455-456.
Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein
JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate
cancer. Proc Natl Acad Sci U S A 1990, 87(22):8751-8755.
Carvalho-Salles AB, Mesquita JC, Tajara EH: Deletion (1)(q12) and double
minutes in a metastatic adenocarcinoma of the prostate. Cancer Genet
Cytogenet 2000, 116(1):50-53.
Chang GT, Steenbeek M, Schippers E, Blok LJ, van Weerden WM, van Alewijk
DC, Eussen BH, van Steenbrugge GJ, Brinkmann AO: A novel gene on human
chromosome 2p24 is differentially expressed between androgen-dependent
and androgen-independent prostate cancer cells. Eur J Cancer 2001,
37(16):2129-2134.
Chang GT, Tapsi N, Steenbeek M, Blok LJ, van Weerden WM, van Alewijk DC,
Eussen BH, van Steenbrugge GJ, Brinkmann AO: Identification of a gene on
human chromosome 8q11 that is differentially expressed during prostatecancer progression. Int J Cancer 1999, 83(4):506-511.
Chekmareva MA, Hollowell CM, Smith RC, Davis EM, LeBeau MM, RinkerSchaeffer CW: Localization of prostate cancer metastasis-suppressor activity
on human chromosome 17. Prostate 1997, 33(4):271-280.
Chekmareva MA, Kadkhodaian MM, Hollowell CM, Kim H, Yoshida BA, Luu
HH, Stadler WM, Rinker-Schaeffer CW: Chromosome 17-mediated dormancy
of AT6.1 prostate cancer micrometastases. Cancer Res 1998, 58(21):49634969.
Chen C, Brabham WW, Stultz BG, Frierson HF, Jr., Barrett JC, Sawyers CL,
Isaacs JT, Dong JT: Defining a common region of deletion at 13q21 in human
cancers. Genes Chromosomes Cancer 2001, 31(4):333-344.
Chen TR: Chromosome identity of human prostate cancer cell lines, PC-3 and
PPC-1. Cytogenet Cell Genet 1993, 62(2-3):183-184.
Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, Park
WS, Moon YW, Tsai ML, Linehan WM et al: Evidence of independent origin
of multiple tumors from patients with prostate cancer. J Natl Cancer Inst
1998, 90(3):233-237.
Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs
WB, Jensen RH: Genetic alterations in untreated metastases and androgen-
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
independent prostate cancer detected by comparative genomic hybridization
and allelotyping. Cancer Res 1996, 56(13):3091-3102.
Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of
physical deletion on chromosome 16q in prostate cancer cells by fluorescence
in situ hybridization (FISH). J Urol 1995, 153(1):249-254.
Cher ML, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, Powell IJ: A
similar pattern of chromosomal alterations in prostate cancers from AfricanAmericans and Caucasian Americans. Clin Cancer Res 1998, 4(5):1273-1278.
Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH:
Comparative genomic hybridization, allelic imbalance, and fluorescence in
situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes
Cancer 1994, 11(3):153-162.
Chu LW, Pettaway CA, Liang JC: Genetic abnormalities specifically associated
with varying metastatic potential of prostate cancer cell lines as detected by
comparative genomic hybridization. Cancer Genet Cytogenet 2001,
127(2):161-167.
Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE,
Oesterling JE, Sandler HM, Lange K: Prostate cancer susceptibility locus on
chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89(13):955959.
Cooney KA, Wetzel JC, Consolino CM, Wojno KJ: Identification and
characterization of proximal 6q deletions in prostate cancer. Cancer Res
1996, 56(18):4150-4153.
Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ:
Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996,
56(5):1142-1145.
Corral Molina JM, Alcaraz Asensio A, Barranco Sanz MA, Mallofre Gomez C,
Ribal Caparros MJ, Cetina Herrando A, Beardo Villar P, Muntane Casasus J,
Llopis Manzaneda J, Carretero Gonzalez P: [High incidence of chromosome 8
monosomy and chromosome 7 trisomy in prostatic primary tumor and its
related lymphatic metastasis. Preliminary results]. Actas Urol Esp 1998,
22(10):811-817.
Crundwell MC, Arkell DG, Gearty J, Phillips SM: Genetic alterations in
incidentally diagnosed, transitional zone prostate cancer: a seven year followup. J Urol 1997, 158(4):1568-1575.
Crundwell MC, Chughtai S, Knowles M, Takle L, Luscombe M, Neoptolemos JP,
Morton DG, Phillips SM: Allelic loss on chromosomes 8p, 22q and 18q (DCC)
in human prostate cancer. Int J Cancer 1996, 69(4):295-300.
Cui J, Deubler DA, Rohr LR, Zhu XL, Maxwell TM, Changus JE, Brothman AR:
Chromosome 7 abnormalities in prostate cancer detected by dual-color
fluorescence in situ hybridization. Cancer Genet Cytogenet 1998, 107(1):51-60.
Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian
J, Takahashi S, Jenkins RB, Bostwick DG et al: Allelic imbalance and
microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996,
56(19):4475-4482.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G: High frequency of
genetic instability of microsatellites in human prostatic adenocarcinoma. Int J
Cancer 1997, 72(5):762-767.
Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, Deng G: Chromosome
3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer
1997, 71(1):20-25.
Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, Deng G: Deletion of
chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J
Cancer 1997, 72(2):283-288.
Dahiya R, Yoon WH, Boyle B, Schoenberg S, Yen TS, Narayan P: Biochemical,
cytogenetic, and morphological characteristics of human primary and
metastatic prostate cancer cell lines. Biochem Int 1992, 27(4):567-577.
Dai Q, Deubler DA, Maxwell TM, Zhu XL, Cui J, Rohr LR, Stephenson RA,
Brothman AR: A common deletion at chromosomal region 17q21 in sporadic
prostate tumors distal to BRCA1. Genomics 2001, 71(3):324-329.
Debruyne FM, Collins VP, van Dekken H, Jenkins RB, Klocker H, Schalken JA,
Sesterhenn IA: Cytogenetics of prostate cancer. Consensus Conference on
Diagnosis and Prognostic Parameters in Localized Prostate Cancer.
Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994,
162:65-71.
Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B,
Calvo F: Recurrent cytogenetic alterations of prostate carcinoma and
amplification of c-myc or epidermal growth factor receptor in subclones of
immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995,
62(6):724-731.
Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, Stephenson
RA, Changus JE, Miller GJ, Becich MJ et al: Allelic loss detected on
chromosomes 8, 10, and 17 by fluorescence in situ hybridization using singlecopy P1 probes on isolated nuclei from paraffin-embedded prostate tumors.
Am J Pathol 1997, 150(3):841-850.
Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF, Jr.: Deletion at 13q21 is
associated with aggressive prostate cancers. Cancer Res 2000, 60(14):38803883.
Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S,
Biggs P, Dearnaley D, Ardern-Jones A et al: Linkage analysis of chromosome
1q markers in 136 prostate cancer families. The Cancer Research
Campaign/British Prostate Group U.K. Familial Prostate Cancer Study
Collaborators. Am J Hum Genet 1998, 62(3):653-658.
El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ,
Sauter G, Gasser TC: Discovery of new DNA amplification loci in prostate
cancer by comparative genomic hybridization. Prostate 2001, 46(3):184-190.
Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko
P: Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with
metastatic and aggressive behavior of prostate cancer. Cancer Res 1997,
57(16):3356-3359.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Vihko P: Three independently
deleted regions at chromosome arm 16q in human prostate cancer: allelic
loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease,
recurrent growth, poor differentiation of the tumour and poor prognosis for
the patient. Br J Cancer 1999, 79(1):156-160.
Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence
CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on
chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia.
Cancer Res 1995, 55(14):2959-2962.
Erbersdobler A, Bardenhagen P, Henke RP: Numerical chromosomal anomalies
in latent adenocarcinomas of the prostate. Prostate 1999, 38(2):92-99.
Erbersdobler A, Gurses N, Henke RP: Numerical chromosomal changes in
high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive
carcinoma. Pathol Res Pract 1996, 192(5):418-427.
Erbersdobler A, Hammerer P, Huland H, Henke RP: Numerical chromosomal
aberrations in transition-zone carcinomas of the prostate. J Urol 1997,
158(4):1594-1598.
Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett
JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate
cancer cells: correlation with re-expression of alpha-catenin and restoration
of E- cadherin function. Cancer Res 1995, 55(21):4813-4817.
Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM: Analysis of PTEN and
the 10q23 region in primary prostate carcinomas. Oncogene 1998,
16(13):1743-1748.
Fiedler U, Ehlers W, Meye A, Fussel S, Faller G, Schmidt U, Wirth MP: LOH
analyses in the region of the putative tumour suppressor gene C13 on
chromosome 13q13. Anticancer Res 2001, 21(4A):2341-2350.
Ford S, Gray IC, Spurr NK: Rearrangement of the long arm of chromosome 10
in the prostate adenocarcinoma cell line LNCaP. Cancer Genet Cytogenet
1998, 102(1):6-11.
Fu W, Bubendorf L, Willi N, Moch H, Mihatsch MJ, Sauter G, Gasser TC:
Genetic changes in clinically organ-confined prostate cancer by comparative
genomic hybridization. Urology 2000, 56(5):880-885.
Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T,
Murakami Y: Functional evidence for the presence of tumor suppressor gene
on chromosome 10p15 in human prostate cancers. Oncogene 2001, 20(3):314319.
Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, Isaacs JT: Suppression
of the tumorigenicity of prostatic cancer cells by gene(s) located on human
chromosome 19p13.1-13.2. Prostate 1999, 38(1):46-54.
Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, Honn KV:
Localization of potential tumor suppressor loci to a < 2 Mb region on
chromosome 17q in human prostate cancer. Oncogene 1995, 11(7):1241-1247.
Gibas Z, Pontes JE, Sandberg AA: Chromosome rearrangements in a
metastatic adenocarcinoma of the prostate. Cancer Genet Cytogenet 1985,
16(4):301-304.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
Gibbs M, Chakrabarti L, Stanford JL, Goode EL, Kolb S, Schuster EF, Buckley
VA, Shook M, Hood L, Jarvik GP et al: Analysis of chromosome 1q42.2-43 in
152 families with high risk of prostate cancer. Am J Hum Genet 1999,
64(4):1087-1095.
Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, Goode EL,
Kolb S, Chakrabarti L, Shook M et al: A genomic scan of families with prostate
cancer identifies multiple regions of interest. Am J Hum Genet 2000,
67(1):100-109.
Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti
L, Schuster EF, Buckley VA, Miller EL et al: Evidence for a rare prostate
cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999,
64(3):776-787.
Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM: Model-free linkage
analysis with covariates confirms linkage of prostate cancer to chromosomes
1 and 4. Am J Hum Genet 2001, 68(5):1197-1206.
Godfrey TE, Cher ML, Chhabra V, Jensen RH: Allelic imbalance mapping of
chromosome 16 shows two regions of common deletion in prostate
adenocarcinoma. Cancer Genet Cytogenet 1997, 98(1):36-42.
Goodarzi G, Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Pai SK, Hirota
S, Hosobe S, Miura K, Bandyopadhyay S et al: Identification of tumor
metastasis suppressor region on the short arm of human chromosome 20.
Genes Chromosomes Cancer 2001, 32(1):33-42.
Goode EL, Stanford JL, Chakrabarti L, Gibbs M, Kolb S, McIndoe RA, Buckley
VA, Schuster EF, Neal CL, Miller EL et al: Linkage analysis of 150 high-risk
prostate cancer families at 1q24-25. Genet Epidemiol 2000, 18(3):251-275.
Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss
of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995,
55(21):4800-4803.
Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers
DA, Collins FS, Trent JM et al: Characteristics of prostate cancer in families
potentially linked to the hereditary prostate cancer 1 (HPC1) locus. Jama
1997, 278(15):1251-1255.
Gronberg H, Smith J, Emanuelsson M, Jonsson BA, Bergh A, Carpten J, Isaacs
W, Xu J, Meyers D, Trent J et al: In Swedish families with hereditary prostate
cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to
families with early- onset prostate cancer. Am J Hum Genet 1999, 65(1):134140.
Gronberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS, Danber
JE, Bergh A, Walsh PC et al: Early age at diagnosis in families providing
evidence of linkage to the hereditary prostate cancer locus (HPC1) on
chromosome 1. Cancer Res 1997, 57(21):4707-4709.
Haggman MJ, Wojno KJ, Pearsall CP, Macoska JA: Allelic loss of 8p sequences
in prostatic intraepithelial neoplasia and carcinoma. Urology 1997, 50(4):643647.
Heidenreich B, Heidenreich A, Sesterhenn A, Srivastava S, Moul JW, Sesterhenn
IA: Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4)
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
and p15(INK4B) detected by in situ hybridization in locally advanced
prostate cancer. Eur Urol 2000, 38(4):475-482.
Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P: Frequency and
distribution of numerical chromosomal aberrations in prostatic cancer. Hum
Pathol 1994, 25(5):476-484.
Hsieh CL, Oakley-Girvan I, Gallagher RP, Wu AH, Kolonel LN, Teh CZ,
Halpern J, West DW, Paffenbarger RS, Jr., Whittemore AS: Re: prostate cancer
susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer
Inst 1997, 89(24):1893-1894.
Hyytinen ER, Frierson HF, Jr., Boyd JC, Chung LW, Dong JT: Three distinct
regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes
Chromosomes Cancer 1999, 25(2):108-114.
Ichikawa T, Hosoki S, Suzuki H, Akakura K, Igarashi T, Furuya Y, Oshimura M,
Rinker-Schaeffer CW, Nihei N, Barrett JC et al: Mapping of metastasis
suppressor genes for prostate cancer by microcell- mediated chromosome
transfer. Asian J Androl 2000, 2(3):167-171.
Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I,
Isaacs JT, Shimazaki J: Suppression of metastasis of rat prostatic cancer by
introducing human chromosome 8. Cancer Res 1994, 54(9):2299-2302.
Isaacs JT, Hukku B: Nonrandom involvement of chromosome 4 in the
progression of rat prostatic cancer. Prostate 1988, 13(2):165-188.
Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM:
Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol
1994, 59:653-659.
Ittmann M: Allelic loss on chromosome 10 in prostate adenocarcinoma.
Cancer Res 1996, 56(9):2143-2147.
Ittmann MM: Loss of heterozygosity on chromosomes 10 and 17 in clinically
localized prostate carcinoma. Prostate 1996, 28(5):275-281.
Jackson-Cook C, Bae V, Edelman W, Brothman A, Ware J: Cytogenetic
characterization of the human prostate cancer cell line P69SV40T and its
novel tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet 1996,
87(1):14-23.
Jarvik GP, Stanford JL, Goode EL, McIndoe R, Kolb S, Gibbs M, Hood L,
Ostrander EA: Confirmation of prostate cancer susceptibility genes using
high-risk families. J Natl Cancer Inst Monogr 1999, 26:81-87.
Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M: Prognostic
significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in
stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 1998, 21(2):131143.
Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J,
Wilber K, Lieber MM, Liu W et al: A molecular cytogenetic analysis of 7q31 in
prostate cancer. Cancer Res 1998, 58(4):759-766.
Jones E, Zhu XL, Rohr LR, Stephenson RA, Brothman AR: Aneusomy of
chromosomes 7 and 17 detected by FISH in prostate cancer and the effects of
selection in vitro. Genes Chromosomes Cancer 1994, 11(3):163-170.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P:
Mapping of chromosomal gains and losses in prostate cancer by comparative
genomic hybridization. Genes Chromosomes Cancer 1995, 14(4):267-276.
Jordan JJ, Hanlon AL, Al-Saleem TI, Greenberg RE, Tricoli JV: Loss of the
short arm of the Y chromosome in human prostate carcinoma. Cancer Genet
Cytogenet 2001, 124(2):122-126.
Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach
AC, Troncoso P: Homozygous deletions at 8p22 and 8p21 in prostate cancer
implicate these regions as the sites for candidate tumor suppressor genes.
Oncogene 1995, 11(10):2121-2126.
Kalapurakal JA, Jacob AN, Kim PY, Najjar DD, Hsieh YC, Ginsberg P, Daskal I,
Asbell SO, Kandpal RP: Racial differences in prostate cancer related to loss of
heterozygosity on chromosome 8p12-23. Int J Radiat Oncol Biol Phys 1999,
45(4):835-840.
Karashima T, Taguchi T, Yoshikawa C, Kamada M, Kasahara K, Yuri K, Shuin
T: Numerical chromosomal changes in metastatic prostate cancer following
anti-androgen therapy: fluorescence in situ hybridization analysis of 5
Japanese cases. Cancer Genet Cytogenet 2000, 120(2):148-154.
Kasahara K, Taguchi T, Inoue K, Shuin T, Kariya S, Yoshida S, Furihata M:
Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly
corrrelated with clinical effect in high-dose rate brachytherapy with external
beam radiotherapy in localized prostate cancer. Int J Mol Med 2001, 8(6):667673.
Kasahara K, Taguchi T, Yamasaki I, Karashima T, Kamada M, Yuri K, Shuin T:
Fluorescence in situ hybridization to assess transitional changes of
aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate
cancer following anti-androgen therapy. Int J Oncol 2001, 19(3):543-549.
Kibel AS, Freije D, Isaacs WB, Bova GS: Deletion mapping at 12p12-13 in
metastatic prostate cancer. Genes Chromosomes Cancer 1999, 25(3):270-276.
Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS: Identification of 12p as a
region of frequent deletion in advanced prostate cancer. Cancer Res 1998,
58(24):5652-5655.
Koivisto PA: Molecular cytogenetics of prostate cancer. Crit Rev Oncog 1996,
7(3-4):143-150.
Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H, Shimazaki J: Allelic
losses at loci on chromosome 10 are associated with metastasis and
progression of human prostate cancer. Genes Chromosomes Cancer 1996,
17(4):245-253.
Konig JJ, Teubel W, Romijn JC, Schroder FH, Hagemeijer A: Gain and loss of
chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 1996,
27(7):720-727.
Konig JJ, Teubel W, van Dongen JW, Romijn JC, Hagemeijer A, Schroder FH:
Loss and gain of chromosomes 1, 18, and Y in prostate cancer. Prostate 1994,
25(6):281-291.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
Konig JJ, Teubel W, van Steenbrugge GJ, Romijn JC, Hagemeijer A:
Characterization of chromosome 8 aberrations in the prostate cancer cell line
LNCaP-FGC and sublines. Urol Res 1999, 27(1):3-8.
Kuramochi H, Ichikawa T, Nihei N, Kawana Y, Suzuki H, Schalken JA, Takeichi
M, Nagafuchi A, Ito H, Shimazaki J: Suppression of invasive ability of highly
metastatic rat prostate cancer by introduction of human chromosome 8.
Prostate 1997, 31(1):14-20.
Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang ZF, Cordon-Cardo
C: Microsatellite instability and deletion analysis of chromosome 10 in
human prostate cancer. Int J Cancer 1996, 69(2):110-113.
Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange
K, Cooney KA: The polymorphic exon 1 androgen receptor CAG repeat in
men with a potential inherited predisposition to prostate cancer. Cancer
Epidemiol Biomarkers Prev 2000, 9(4):439-442.
Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E, Ray ME,
Cooney KA: Linkage analysis of 153 prostate cancer families over a 30-cM
region containing the putative susceptibility locus HPCX. Clin Cancer Res
1999, 5(12):4013-4020.
Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Le Duc
A, Rouesse J, Lidereau R: Genetic alterations in localized prostate cancer:
identification of a common region of deletion on chromosome arm 18q. Genes
Chromosomes Cancer 1994, 11(2):119-125.
Latil A, Bieche I, Pesche S, Volant A, Valeri A, Fournier G, Cussenot O,
Lidereau R: Loss of heterozygosity at chromosome arm 13q and RB1 status in
human prostate cancer. Hum Pathol 1999, 30(7):809-815.
Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R: Loss of heterozygosity
at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res
1995, 1(11):1385-1389.
Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R: Loss of heterozygosity
at chromosome 16q in prostate adenocarcinoma: identification of three
independent regions. Cancer Res 1997, 57(6):1058-1062.
Latil A, Cussenot O, Fournier G, Lidereau R: Infrequent allelic imbalance at
the major susceptibility HPC1 locus in sporadic prostate tumours. Int J
Cancer 1997, 71(6):1118.
Latil A, Fournier G, Cussenot O, Lidereau R: Differential chromosome allelic
imbalance in the progression of human prostate cancer. J Urol 1996,
156(6):2079-2083.
Latil A, Guerard M, Berthon P, Cussenot O: 12p12-13 deletion in prostate
tumors and quantitative expression of CDKN1B and ETV6 candidate genes.
Genes Chromosomes Cancer 2001, 31(2):199-200.
Li C, Berx G, Larsson C, Auer G, Aspenblad U, Pan Y, Sundelin B, Ekman P,
Nordenskjold M, van Roy F et al: Distinct deleted regions on chromosome
segment 16q23-24 associated with metastases in prostate cancer. Genes
Chromosomes Cancer 1999, 24(3):175-182.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu
Y, Ekman P, Auer G et al: Identification of two distinct deleted regions on
chromosome 13 in prostate cancer. Oncogene 1998, 16(4):481-487.
Lundgren R: Cytogenetic studies of prostatic cancer. Scand J Urol Nephrol
Suppl 1991, 136:1-35.
Lundgren R, Kristoffersson U, Heim S, Mandahl N, Mitelman F: Multiple
structural chromosome rearrangements, including del(7q) and del(10q), in
an adenocarcinoma of the prostate. Cancer Genet Cytogenet 1988, 35(1):103108.
Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F:
Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes
Chromosomes Cancer 1992, 4(1):16-24.
Lutchman M, Pack S, Kim AC, Azim A, Emmert-Buck M, van Huffel C, Zhuang
Z, Chishti AH: Loss of heterozygosity on 8p in prostate cancer implicates a
role for dematin in tumor progression. Cancer Genet Cytogenet 1999,
115(1):65-69.
MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of
chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic
imbalance. Genes Chromosomes Cancer 1994, 10(3):151-159.
Macintosh CA, Stower M, Reid N, Maitland NJ: Precise microdissection of
human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998,
58(1):23-28.
Macoska JA, Beheshti B, Rhim JS, Hukku B, Lehr J, Pienta KJ, Squire JA:
Genetic characterization of immortalized human prostate epithelial cell
cultures. Evidence for structural rearrangements of chromosome 8 and i(8q)
chromosome formation in primary tumor-derived cells. Cancer Genet
Cytogenet 2000, 120(1):50-57.
Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR: Extensive genetic
alterations in prostate cancer revealed by dual PCR and FISH analysis.
Genes Chromosomes Cancer 1993, 8(2):88-97.
Macoska JA, Powell IJ, Sakr W, Lane MA: Loss of the 17p chromosomal
region in a metastatic carcinoma of the prostate. J Urol 1992, 147(4):11421146.
Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk
T, Powell IJ: Evidence for three tumor suppressor gene loci on chromosome
8p in human prostate cancer. Cancer Res 1995, 55(22):5390-5395.
Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE:
Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome
8 instability in human prostate cancer. Cancer Res 1994, 54(14):3824-3830.
Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Rinker-Schaeffer CW, Helfer
E, Watabe K: Human chromosome 16 suppresses metastasis but not
tumorigenesis in rat prostatic tumor cells. Cancer Res 1998, 58(20):4572-4576.
Matsuura H, Shiraishi T, Yatani R, Kawamura J: Interphase cytogenetics of
prostate cancer: fluorescence in situ hybridisation (FISH) analysis of
Japanese cases. Br J Cancer 1996, 74(11):1699-1704.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hagarth L, Kudren D,
Naito K, Bergerheim US, Ekman P: Deletions on chromosome 8p22 may
predict disease progression as well as pathological staging in prostate cancer.
Clin Cancer Res 2001, 7(10):3139-3143.
Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P,
Bergerheim US: Deletion mapping of chromosome 8p in prostate cancer by
fluorescence in situ hybridization. Oncogene 1994, 9(10):3071-3076.
Matturri L, Biondo B, Cazzullo A, Montanari E, Radice F, Timossi R, Turconi P,
Lavezzi AM: Detection of trisomy 7 with fluorescence in situ hybridization
and its correlation with DNA content and proliferating cell nuclear antigenpositivity in prostate cancer. Am J Clin Oncol 1998, 21(3):253-257.
McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S,
Gammack JT, Gay AA, Goode EL et al: Linkage analysis of 49 high-risk
families does not support a common familial prostate cancer-susceptibility
gene at 1q24-25. Am J Hum Genet 1997, 61(2):347-353.
Melamed J, Einhorn JM, Ittmann MM: Allelic loss on chromosome 13q in
human prostate carcinoma. Clin Cancer Res 1997, 3(10):1867-1872.
Mesker WE, Alers JC, Sloos WC, Vrolijk H, Raap AK, Dekken HV, Tanke HJ:
Automated assessment of numerical chromosomal aberrations in paraffin
embedded prostate tumor cells stained by in situ hybridization. Cytometry
1996, 26(4):298-304.
Micale MA, Mohamed A, Sakr W, Powell IJ, Wolman SR: Cytogenetics of
primary prostatic adenocarcinoma. Clonality and chromosome instability.
Cancer Genet Cytogenet 1992, 61(2):165-173.
Milasin J, Micic S: Double minute chromosomes in an invasive
adenocarcinoma of the prostate. Cancer Genet Cytogenet 1994, 72(2):157-159.
Molenaar WM, Stoepker ME, de Ruiter AJ, Hoekstra HJ, van den Berg E:
Cytogenetic support for primary prostatic cancer in a patient presenting
with a soft tissue mass in the leg. Cancer Genet Cytogenet 1996, 86(2):147-149.
Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK,
Henderson BE: Evidence of an X-linked or recessive genetic component to
prostate cancer risk. Nat Med 1995, 1(8):827-829.
Morton RA, Jr., Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB:
Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue.
J Urol 1996, 156(2 Pt 1):512-516.
Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of
the malignant phenotype of human prostate cancer cell line PPC-1 by
introduction of normal fragments of human chromosome 10. Cancer Res
1996, 56(9):2157-2160.
Murakami YS, Brothman AR, Leach RJ, White RL: Suppression of malignant
phenotype in a human prostate cancer cell line by fragments of normal
chromosomal region 17q. Cancer Res 1995, 55(15):3389-3394.
Neuhausen SL, Farnham JM, Kort E, Tavtigian SV, Skolnick MH, CannonAlbright LA: Prostate cancer susceptibility locus HPC1 in Utah high-risk
pedigrees. Hum Mol Genet 1999, 8(13):2437-2442.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary
AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT et al: Localization of
metastasis suppressor gene(s) for rat prostatic cancer to the long arm of
human chromosome 10. Genes Chromosomes Cancer 1995, 14(2):112-119.
Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugoh H, Oshimura M, Hayata I,
Shimazaki J, Ito H: Mapping of metastasis suppressor gene(s) for rat prostate
cancer on the short arm of human chromosome 8 by irradiated microcellmediated chromosome transfer. Genes Chromosomes Cancer 1996, 17(4):260268.
Nihei N, Ohta S, Kuramochi H, Kugoh H, Oshimura M, Barrett JC, Isaacs JT,
Igarashi T, Ito H, Masai M et al: Metastasis suppressor gene(s) for rat prostate
cancer on the long arm of human chromosome 7. Genes Chromosomes Cancer
1999, 24(1):1-8.
Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in
hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998,
153(1):141-148.
Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo
M, Sagiyama K, Naito K: Two putative tumor suppressor genes on
chromosome arm 8p may play different roles in prostate cancer. Cancer
Genet Cytogenet 2001, 124(1):20-26.
Osman I, Scher H, Dalbagni G, Reuter V, Zhang ZF, Cordon-Cardo C:
Chromosome 16 in primary prostate cancer: a microsatellite analysis. Int J
Cancer 1997, 71(4):580-584.
Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ,
von Eschenbach AC, Pathak S: Correlation of non-random chromosomal
aberrations in lymphocytes of prostate cancer patients with specific clinical
parameters. Int J Oncol 2000, 17(1):113-117.
Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von
Eschenbach AC, Pathak S: Structural alterations of chromosome 5 in twelve
human prostate cancer cell lines. Cancer Genet Cytogenet 1998, 106(2):105109.
Padalecki SS, Johnson-Pais TL, Killary AM, Leach RJ: Chromosome 18
suppresses the tumorigenicity of prostate cancer cells. Genes Chromosomes
Cancer 2001, 30(3):221-229.
Padalecki SS, Troyer DA, Hansen MF, Saric T, Schneider BG, O'Connell P,
Leach RJ: Identification of two distinct regions of allelic imbalance on
chromosome 18Q in metastatic prostate cancer. Int J Cancer 2000, 85(5):654658.
Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF,
Porteous DJ, Watson JE: A 700-kb physical map of a region of 16q23.2
homozygously deleted in multiple cancers and spanning the common fragile
site FRA16D. Cancer Res 2000, 60(6):1690-1697.
Paiss T, Bochum S, Herkommer K, Maier C, Roesch K, Taweemonkonsap T,
Haeussler J, Hautmann RE, Vogel W: Hereditary prostate cancer in germany.
Eur Urol 2001, 39 Suppl 4:12-18.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim US,
Kytola S: 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in
prostate cancer cell lines. Genes Chromosomes Cancer 2001, 30(2):187-195.
Paris PL, Witte JS, Kupelian PA, Levin H, Klein EA, Catalona WJ, Casey G:
Identification and fine mapping of a region showing a high frequency of
allelic imbalance on chromosome 16q23.2 that corresponds to a prostate
cancer susceptibility locus. Cancer Res 2000, 60(13):3645-3649.
Perinchery G, Bukurov N, Nakajima K, Chang J, Hooda M, Oh BR, Dahiya R:
Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate
cancer. Int J Oncol 1999, 14(3):495-500.
Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R: High
frequency of deletion on chromosome 9p21 may harbor several tumorsuppressor genes in human prostate cancer. Int J Cancer 1999, 83(5):610-614.
Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R: Deletion of Ychromosome specific genes in human prostate cancer. J Urol 2000,
163(4):1339-1342.
Peters MA, Jarvik GP, Janer M, Chakrabarti L, Kolb S, Goode EL, Gibbs M,
DuBois CC, Schuster EF, Hood L et al: Genetic linkage analysis of prostate
cancer families to Xq27-28. Hum Hered 2001, 51(1-2):107-113.
Powell IJ, Meyskens FL, Jr.: African American men and hereditary/familial
prostate cancer: Intermediate-risk populations for chemoprevention trials.
Urology 2001, 57(4 Suppl 1):178-181.
Prasad MA, Trybus TM, Wojno KJ, Macoska JA: Homozygous and frequent
deletion of proximal 8p sequences in human prostate cancers: identification
of a potential tumor suppressor gene site. Genes Chromosomes Cancer 1998,
23(3):255-262.
Qi H, Dal Cin P, Van de Voorde W, Elgamal AA, Van Poppel H, Baert L, Van
Den Berghe H: del(1)(q12) in adenocarcinomas of the prostate. Cancer Genet
Cytogenet 1996, 87(1):79-81.
Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong J, Stoica G, Griffin CA,
Ichikawa T, Barrett JC, Isaacs JT: Differential suppression of mammary and
prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res
1994, 54(23):6249-6256.
Rohrbach H, Haas CJ, Baretton GB, Hirschmann A, Diebold J, Behrendt RP,
Lohrs U: Microsatellite instability and loss of heterozygosity in prostatic
carcinomas: comparison of primary tumors, and of corresponding
recurrences after androgen-deprivation therapy and lymph-node metastases.
Prostate 1999, 40(1):20-27.
Rokman A, Koivisto PA, Matikainen MP, Kuukasjarvi T, Poutiainen M, Helin
HJ, Karhu R, Kallioniemi OP, Schleutker J: Genetic changes in familial
prostate cancer by comparative genomic hybridization. Prostate 2001,
46(3):233-239.
Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R,
Papadopoulos N: 10q23.3 loss of heterozygosity is higher in lymph nodepositive (pT2- 3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.
Hum Pathol 2000, 31(4):504-508.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
Sandberg AA: Chromosomal abnormalities and related events in prostate
cancer. Hum Pathol 1992, 23(4):368-380.
Sandberg AA: Cytogenetic and molecular genetic aspects of human prostate
cancer: primary and metastatic. Adv Exp Med Biol 1992, 324:45-75.
Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB:
Clinical significance of alterations of chromosome 8 in high-grade, advanced,
nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999, 91(18):1574-1580.
Sattler HP, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H, Retz M,
Zwergel T, Bex A, Stoeckle M et al: Novel amplification unit at chromosome
3q25-q27 in human prostate cancer. Prostate 2000, 45(3):207-215.
Schaid DJ, McDonnell SK, Thibodeau SN: Regression models for linkage
heterogeneity applied to familial prostate cancer. Am J Hum Genet 2001,
68(5):1189-1196.
Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T,
Gillanders E, Sankila R, Pukkala E, Carpten J et al: A genetic epidemiological
study of hereditary prostate cancer (HPC) in Finland: frequent HPCX
linkage in families with late-onset disease. Clin Cancer Res 2000, 6(12):48104815.
Singh R: No evidence of linkage to chromosome 1q42.2-43 in 131 prostate
cancer families from the ACTANE consortium. Anglo, Canada, Texas,
Australia, Norway, EU Biomed. Br J Cancer 2000, 83(12):1654-1658.
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ,
Bova GS, Guo H, Bujnovszky P et al: Major susceptibility locus for prostate
cancer on chromosome 1 suggested by a genome-wide search. Science 1996,
274(5291):1371-1374.
Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta LA,
Bostwick DG, Linehan WM, Vocke CD: Chromosome 16 allelic loss analysis of
a large set of microdissected prostate carcinomas. J Urol 1999, 162(2):590594.
Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona
WJ: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2
in multiplex families and healthy controls. Cancer Res 2001, 61(13):49824984.
Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard
KA, Witte JS, Elston RC, Catalona WJ: A genome screen of multiplex sibships
with prostate cancer. Am J Hum Genet 2000, 66(3):933-944.
Suarez BK, Lin J, Witte JS, Conti DV, Resnick MI, Klein EA, Burmester JK,
Vaske DA, Banerjee TK, Catalona WJ: Replication linkage study for prostate
cancer susceptibility genes. Prostate 2000, 45(2):106-114.
Sunwoo JB, Sun PC, Gupta VK, Schmidt AP, El-Mofty S, Scholnick SB:
Localization of a putative tumor suppressor gene in the sub-telomeric region
of chromosome 8p. Oncogene 1999, 18(16):2651-2655.
Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y, Shimazaki J:
Localization of a tumor suppressor gene associated with progression of
human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes
Chromosomes Cancer 1995, 13(3):168-174.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J:
Three distinct commonly deleted regions of chromosome arm 16q in human
primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996,
17(4):225-233.
Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber
MM, Jenkins RB: Aneusomies of chromosomes 8 and Y detected by
fluorescence in situ hybridization are prognostic markers for pathological
stage C (pt3N0M0) prostate carcinoma. Clin Cancer Res 1996, 2(1):137-145.
Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins
RB: Potential markers of prostate cancer aggressiveness detected by
fluorescence in situ hybridization in needle biopsies. Cancer Res 1994,
54(13):3574-3579.
Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM,
Thibodeau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in
primary prostate cancer is associated with tumor aggressiveness and
progression. Cancer Res 1995, 55(18):4114-4119.
Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ,
Carillo AR, Chen Y, Dayananth P et al: A candidate prostate cancer
susceptibility gene at chromosome 17p. Nat Genet 2001, 27(2):172-180.
Teixeira MR, Waehre H, Lothe RA, Stenwig AE, Pandis N, Giercksky KE, Heim
S: High frequency of clonal chromosome abnormalities in prostatic
neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy.
Genes Chromosomes Cancer 2000, 28(2):211-219.
Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder
FH, Faber PW, Bosman FT: Loss of heterozygosity of chromosome 8
microsatellite loci implicates a candidate tumor suppressor gene between the
loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994,
54(23):6061-6064.
Tricoli JV: Y chromosome enumeration in touch preparations from 42
prostate tumors by interphase fluorescence in situ hybridization analysis.
Cancer Genet Cytogenet 1999, 111(1):1-6.
Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA: Distinct areas of
allelic loss on chromosomal regions 10p and 10q in human prostate cancer.
Cancer Res 1996, 56(10):2263-2267.
Uchida T, Wang C, Sato T, Gao J, Takashima R, Irie A, Ohori M, Koshiba K:
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in
primary prostate cancer. Int J Cancer 1999, 84(1):19-23.
Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T, Watanabe M,
Shiraishi T, Masai M, Igarashi T et al: Identification of a I-cM region of
common deletion on 13q14 associated with human prostate cancer. Genes
Chromosomes Cancer 1999, 24(3):183-190.
Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda
K, Ito H: Allelic losses on 18q21 are associated with progression and
metastasis in human prostate cancer. Genes Chromosomes Cancer 1997,
20(2):140-147.
224.
225.
226.
227.
228.
229.
230.
231.
232.
233.
234.
235.
236.
237.
Valeri A, Drelon E, Paiss T, Vogel W, de Petriconi R, Hautmann R, Fournier G,
Mangin P, Berthon P, Cussenot O: [Genetic analysis of familial prostatic
cancer: localization of a gene predisposing to prostatic cancer (PCaP) on
chromosome 1q 42.2-43]. Prog Urol 1999, 9(4):680-688.
Van Alewijk DC, Van der Weiden MM, Eussen BJ, Van Den Andel-Thijssen LD,
Ehren-van Eekelen CC, Konig JJ, van Steenbrugge GJ, Dinjens WN, Trapman J:
Identification of a homozygous deletion at 8p12-21 in a human prostate
cancer xenograft. Genes Chromosomes Cancer 1999, 24(2):119-126.
Van Dekken H, Alers J: Loss of chromosome Y in prostatic cancer cells but
not in stromal tissue. Cancer Genet Cytogenet 1993, 66(2):131-132.
Van Dekken H, Krijtenburg PJ, Alers JC: DNA in situ hybridization
(interphase cytogenetics) versus comparative genomic hybridization (CGH)
in human cancer: detection of numerical and structural chromosome
aberrations. Acta Histochem 2000, 102(1):85-94.
Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin C,
Kallioniemi O, Visakorpi, McGill, Herath J et al: DNA sequence amplification
in human prostate cancer identified by chromosome microdissection:
potential prognostic implications. Clin Cancer Res 1995, 1(1):11-18.
van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM,
Schalken JA: Karyometric analysis of intra-tumour heterogeneity in prostate
adenocarcinoma. Anal Cell Pathol 1994, 7(2):153-170.
Virgin JB, Hurley PM, Nahhas FA, Bebchuk KG, Mohamed AN, Sakr WA,
Bright RK, Cher ML: Isochromosome 8q formation is associated with 8p loss
of heterozygosity in a prostate cancer cell line. Prostate 1999, 41(1):49-57.
Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP: Sensitive
detection of chromosome copy number aberrations in prostate cancer by
fluorescence in situ hybridization. Am J Pathol 1994, 145(3):624-630.
Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T,
Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate
cancer by comparative genomic hybridization. Cancer Res 1995, 55(2):342347.
Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE,
Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM: Analysis of 99
microdissected prostate carcinomas reveals a high frequency of allelic loss on
chromosome 8p12-21. Cancer Res 1996, 56(10):2411-2416.
Wake N, Isaacs J, Sandberg AA: Chromosomal changes associated with
progression of the Dunning R-3327 rat prostatic adenocarcinoma system.
Cancer Res 1982, 42(10):4131-4142.
Webb HD, Hawkins AL, Griffin CA: Cytogenetic abnormalities are frequent in
uncultured prostate cancer cells. Cancer Genet Cytogenet 1996, 88(2):126-132.
Whittemore AS, Lin IG, Oakley-Girvan I, Gallagher RP, Halpern J, Kolonel LN,
Wu AH, Hsieh CL: No evidence of linkage for chromosome 1q42.2-43 in
prostate cancer. Am J Hum Genet 1999, 65(1):254-256.
Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E,
Hummerich J, Muller DJ, Stangl AP, Schramm J et al: Evidence for a novel
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.
249.
250.
tumor suppressor gene on chromosome 15 associated with progression to a
metastatic stage in breast cancer. Oncogene 1996, 12(5):973-978.
Williams BJ, Jones E, Brothman AR: Homologous centromere association of
chromosomes 9 and 17 in prostate cancer. Cancer Genet Cytogenet 1995,
85(2):143-151.
Wu SQ, Hafez GR, Zhang J, Newton M, Chen A, Lange J, Wilding G:
Identification of the prostate cancer micro-foci with chromosome 8p deletion
at the tumor interface area by histopathological-FISH parallel examination.
Int J Oncol 2001, 19(6):1143-1147.
Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E,
Bujnovszky P, Bova GS et al: Evidence for a prostate cancer susceptibility
locus on the X chromosome. Nat Genet 1998, 20(2):175-179.
Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley
KE, Henning L, Ewing C et al: Linkage of prostate cancer susceptibility loci to
chromosome 1. Hum Genet 2001, 108(4):335-345.
Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang
B, Ewing CM, Bujnovszky P et al: Linkage and association studies of prostate
cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet 2001,
69(2):341-350.
Yaremko ML, Recant WM, Westbrook CA: Loss of heterozygosity from the
short arm of chromosome 8 is an early event in breast cancers. Genes
Chromosomes Cancer 1995, 13(3):186-191.
Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan
J: Limiting the location of putative human prostate cancer tumor suppressor
genes on chromosome 18q. Oncogene 2001, 20(18):2273-2280.
Yin Z, Spitz MR, Babaian RJ, Strom SS, Troncoso P, Kagan J: Limiting the
location of a putative human prostate cancer tumor suppressor gene at
chromosome 13q14.3. Oncogene 1999, 18(52):7576-7583.
Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ: Loss of
heterozygosity in human primary prostate carcinomas: a possible tumor
suppressor gene at 7q31.1. Cancer Res 1994, 54(24):6370-6373.
Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent
JM, Meyers DA, Isaacs WB: Evidence for a prostate cancer linkage to
chromosome 20 in 159 hereditary prostate cancer families. Hum Genet 2001,
108(5):430-435.
Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, Bauchinger
M, Werner M: Chromosomal changes during development and progression of
prostate adenocarcinomas. Br J Cancer 2001, 84(2):202-208.
Zitzelsberger H, Szucs S, Robens E, Weier HU, Hofler H, Bauchinger M:
Combined cytogenetic and molecular genetic analyses of fifty-nine untreated
human prostate carcinomas. Cancer Genet Cytogenet 1996, 90(1):37-44.
Zitzelsberger H, Szucs S, Weier HU, Lehmann L, Braselmann H, Enders S,
Schilling A, Breul J, Hofler H, Bauchinger M: Numerical abnormalities of
chromosome 7 in human prostate cancer detected by fluorescence in situ
hybridization (FISH) on paraffin- embedded tissue sections with centromerespecific DNA probes. J Pathol 1994, 172(4):325-335.